100% Of Pharma Earnings Growth Last Year Came From Price RisesRupert Hargreaves
Drug pricing has been a hot issue for the past few years and was debated multiple times on the campaign trail by both Trump and Hillary. So far, there’s been little action to curb drug price increases, however, with Trump more focused on arguing with the press and other lawmakers occupied with more urgent matters. For the pharma sector, this is good news, although patients are hardly celebrating.
Still, while it may seem . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email email@example.com and we will get back to you as quick as humanly possible